Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05716087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05716087 · ClinicalTrials.gov record · last posted 2026-01-15

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started2023-02-21
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2023-01-28; most recent amendment 2026-01-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-12-11
Status change Recruiting→Active, Not Recruitingv4
2023-08-29
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05716087
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Mantle Cell Lymphoma (MCL)
Enrollment 62 participants
Start Date 2023-02-21
Primary Completion 2024-12-05 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-15